Think GLP-1s Are Too Expensive for Your Health Plan? Cutting Them Might Hurt Your Bottom Line

Companies may be underestimating the financial benefits of covering weight-loss medications like Ozempic. A recent study shows that removing coverage for these GLP-1 drugs could lead to a significant loss in productivity, costing employers up to $866 per worker annually. This finding underscores the broader economic implications of health plan decisions, suggesting that what might seem like a cost-saving measure could actually hurt a company's bottom line in the long run. The research highlights the need for a more holistic view of health benefits and their impact on overall business performance.